A Phase 3 interventional study of Ranibizumab and Sham control in Choroidal Neovascularization (CNV), sponsored by Novartis Pharmaceuticals. Completed at 59 sites in 21 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2016-08-26.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies testing ranibizumab in Choroidal Neovascularization — none open to participants now, none under way, none of them phase 3. Ranibizumab · Choroidal Neovascularization.
Among the 45 studies testing ranibizumab in Choroidal Neovascularization, this one is the 14th largest by enrollment, is one of 6 that started in 2013, is one of 11 in phase 3, and was the 33rd registered.
214 studies on the registry are indexed under Choroidal Neovascularization; 12 are open to participants now.
Browse Choroidal Neovascularization studies →None of the 45 studies testing ranibizumab in Choroidal Neovascularization is open now. The open studies under Choroidal Neovascularization, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 6 Choroidal Neovascularization studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 15 · Phase 3 12 · Phase 4 12
First in 2005; this study’s year is marked. 6 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 183 is above the median of 56 across 160 interventional studies indexed under Choroidal Neovascularization.
Median enrollment 62 across the 45 interventional studies. Of the 44 that completed or were terminated, 23 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 45 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
29 studies in Choroidal Neovascularization by Novartis: none open now, none under way, none of them phase 3. Of 29 finished, 22 (76%) have results posted.
Among the 29 studies in Choroidal Neovascularization by Novartis, this one is the 16th largest by enrollment of the 28 interventional ones that give a count, is one of 5 that started in 2013, is one of 14 in phase 3, and was the 16th registered.
Novartis’s Choroidal Neovascularization studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 45 studies testing ranibizumab in Choroidal Neovascularization, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 29 in Choroidal Neovascularization:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study was conducted to evaluate the efficacy and safety of 0.5 mg ranibizumab in adult and adolescent patients with visual impairment due to choridal neovascularization (CNV).
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
Drug: Ranibizumab
Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At Month 1, if treatment was needed, sham was administered. At Month 2, participants could switch to open-label ranibizumab on an as needed basis.
Other: Sham control
Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant.
The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.
Change From Baseline in Best-corrected Visual Acuity (BCVA) in Study Eye to Month 2
BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. The data were analyzed using mixed model repeated measures (MMRM) which contained scheduled visit, the type of underlying pathophysiologic mechanism (angloid streaks versus others) and treatment group as fixed effect factors, centered baseline BCVA as a continuous covariate and treatment group by visit and visit by centered baseline BCVA interactions. A positive change from baseline indicated improvement.
Time frame: Baseline, Month 2
Change From Baseline in BCVA in Study Eye up to Month 2
BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. The data were analyzed using analysis of covariance (ANCOVA) model which contained the type of underlying pathophysiologic mechanism (angloid streaks versus others) and treatment group as fixed effect factors, centered baseline BCVA as a continuous covariate. A positive change from baseline indicated improvement.
Time frame: Baseline, Month 1, Month 2
Change From Baseline in Central Subfield Thickness (CSFT) in Study Eye
CSFT was assessed by optical coherence tomography (OCT). A negative change from baseline indicates improvement.
Time frame: Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Change From Baseline in Central Subfield Volume (CSFV) in Study Eye
CSFV was assessed OCT. A negative change from baseline indicates improvement.
Time frame: Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Number of Participants With Presence of Intra-retinal Fluid in Study Eye Compared to Baseline
The presence of intra-retinal fluid was assessed by OCT.
Time frame: Baseline, Month 2, Month 6, Month 12
Number of Participants With Presence of Subretinal Fluid in Study Eye Compared to Baseline
Presence of subretinal fluid in study eye compared to baseline
Time frame: Baseline, Month 2, Month 6, Month 12
Number of Participants With Presence of Active Chorioretinal Leakage
The presence of active chorioretinal leakage was assessed by photography imaging, i.e. fluorescein angiography (FA).
Time frame: Baseline, Month 2, Month 6, Month 12
Average Change From Baseline in BCVA
BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. BCVA was assessed at each month from Month 1 through Month 6 or at each month from Month 1 through month 12, and the data were averaged. The outcome measure is reporting the change between baseline and average BCVA from Month 1 through Month 6 or from Month 1 through Month 12 (average BCVA - baseline BCVA). A positive change from baseline indicated improvement.
Time frame: Baseline (BL), Month 1 through Month 6, Month 1 through Month 12
Number of Participants With ≥ 1, ≥ 5, ≥ 10 and ≥ 15 Letters Gain or Reaching 84 Letters
VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using ETDRS-like visual acuity testing charts at a testing distance of 4 meters.
Time frame: Month 2, Month 6, Month 12
Number of Participants With > 1, > 5, > 10 and > 15 Letters Loss
VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using ETDRS-like visual acuity testing charts at a testing distance of 4 meters.
Time frame: Month 2, Month 6, Month 12
Number of Participants With Requirement for Rescue Treatment at Month 1
Rescue treatment with laser photocoagulation or periocular treatment could be administered at Month 1 only if the participant had a visual acuity loss of \> 5 letters due to disease activity from baseline to Month 1.
Time frame: Month 1
Number of Participants With Ranibizumab Treatments in Study Eye
The number of participants administered study treatments, according to treatment frequency, was assessed.
Time frame: Month 12
Number of Participants With Re-treatments
The number of participants, administered re-treatments according to treatment frequency, was assessed. Re-treatment was defined as an administration of study medication following at least one non-missed visit where treatment was not administered in the study eye. Up to month 12, the maximum number of retreatments was 5.
Time frame: Month 12
Number of Primary Reasons for Decision to Treat by Investigator
The total number of primary reasons for decisions to treat was assessed. A single participant could have had multiple primary reasons for treatment.
Time frame: Month 12
| Milestone | Ranibizumab | Sham Control |
|---|---|---|
| Started | 119 | 59 |
| Safety set | 119 | 59 |
| Full analysis set | 119 | 59 |
| Completed | 112 | 55 |
| Not completed | 7 | 4 |
| Withdrew: Physician decision | 1 | 2 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Protocol deviation | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Adverse event | 1 | 1 |
BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. The data were analyzed using mixed model repeated measures (MMRM) which contained scheduled visit, the type of underlying pathophysiologic mechanism (angloid streaks versus others) and treatment group as fixed effect factors, centered baseline BCVA as a continuous covariate and treatment group by visit and visit by centered baseline BCVA interactions. A positive change from baseline indicated improvement.
| letters | Ranibizumab | Sham Control |
|---|---|---|
| Change From Baseline in Best-corrected Visual Acuity (BCVA) in Study Eye to Month 2 | 9.5 ± 0.95 | -0.4 ± 1.16 |
BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. The data were analyzed using analysis of covariance (ANCOVA) model which contained the type of underlying pathophysiologic mechanism (angloid streaks versus others) and treatment group as fixed effect factors, centered baseline BCVA as a continuous covariate. A positive change from baseline indicated improvement.
| letters | Ranibizumab | Sham Control |
|---|---|---|
| Month 1 | 7.1 ± 0.75 | 0.1 ± 1.08 |
| Month 2 | 9.5 ± 0.91 | -0.4 ± 1.31 |
CSFT was assessed by optical coherence tomography (OCT). A negative change from baseline indicates improvement.
| micrometer (um) | Ranibizumab | Sham Control |
|---|---|---|
| Month 1 (n=115,56) | -74.4 ± 81.25 | 3.3 ± 89.43 |
| Month 2 (n=114,54) | -76.4 ± 108.24 | 1.9 ± 119.44 |
| Month 3 (n=114,56) | -82.9 ± 114.26 | -59.1 ± 142.37 |
| Month 4 (n=114,56) | -83.5 ± 104.71 | -68.4 ± 155.26 |
| Month 5 (n=116,55) | -83.8 ± 112.41 | -89.4 ± 130.68 |
| Month 6 (n=112,54) | -89.1 ± 109.19 | -85.9 ± 117.54 |
| Month 7 (n=114,55) | -83.1 ± 105.97 | -84.5 ± 141.36 |
| Month 8 (n=111,55) | -94.7 ± 111.54 | -97.9 ± 118.34 |
| Month 9 (n=110,55) | -90.0 ± 112.44 | -93.5 ± 113.88 |
| Month 10 (n=108,53) | -100.5 ± 119.45 | -85.4 ± 136.90 |
| Month 11 (n=110,55) | -99.5 ± 112.38 | -82.8 ± 158.78 |
| Month 12 (n=109,55) | -102.7 ± 117.27 | -91.7 ± 152.36 |
CSFV was assessed OCT. A negative change from baseline indicates improvement.
| microliter (ul) | Ranibizumab | Sham Control |
|---|---|---|
| Month 1 (n=115,56) | -0.354 ± 0.4103 | 0.012 ± 0.3608 |
| Month 2 (n=114,54) | -0.357 ± 0.5480 | -0.006 ± 0.5792 |
| Month 3 (n=114,56) | -0.369 ± 0.5506 | -0.269 ± 0.6583 |
| Month 4 (n=114,56) | -0.371 ± 0.4798 | -0.291 ± 0.7647 |
| Month 5 (n=116,55) | -0.392 ± 0.5404 | -0.381 ± 0.5750 |
| Month 6 (n=112,54) | -0.409 ± 0.5305 | -0.375 ± 0.5310 |
| Month 7 (n=114,54) | -0.366 ± 0.4905 | -0.374 ± 0.5966 |
| Month 8 (n=110,55) | -0.414 ± 0.5021 | -0.411 ± 0.4970 |
| Month 9 (n=110,55) | -0.404 ± 0.5182 | -0.413 ± 0.5251 |
| Month 10 (n=108,53) | -0.437 ± 0.5506 | -0.385 ± 0.5688 |
| Month 11 (n=110,55) | -0.448 ± 0.5285 | -0.352 ± 0.7021 |
| Month 12 (n=109,55) | -0.441 ± 0.5460 | -0.378 ± 0.6704 |
The presence of intra-retinal fluid was assessed by OCT.
| Participants | Ranibizumab | Sham Control |
|---|---|---|
| Baseline, Absent (n=116,56) | 70 | 32 |
| Baseline, Definite (n=116,56) | 46 | 24 |
| Month 2, Absent (n=116,56) | 97 | 29 |
| Month 2, Definite (n=116,56) | 19 | 27 |
| Month 6, Absent (n=116,54) | 100 | 43 |
| Month 6, Definite (n=116,54) | 16 | 11 |
| Month 12, Absent (n=111,55) | 95 | 45 |
| Month 12, Definite (n=111,55) | 16 | 10 |
Presence of subretinal fluid in study eye compared to baseline
| Participants | Ranibizumab | Sham Control |
|---|---|---|
| Baseline, Absent (n=116,56) | 16 | 6 |
| Baseline, Definite (n=116,56) | 100 | 50 |
| Month 2, Absent (n=116,56) | 72 | 11 |
| Month 2, Definite (n=116,56) | 44 | 45 |
| Month 6, Absent (n=116,54) | 77 | 34 |
| Month 6, Definite (n=116,54) | 39 | 20 |
| Month 12, Absent (n=111,55) | 78 | 41 |
| Month 12, Definite (n=111,55) | 33 | 14 |
The presence of active chorioretinal leakage was assessed by photography imaging, i.e. fluorescein angiography (FA).
| Participants | Ranibizumab | Sham Control |
|---|---|---|
| Baseline, Absent (n=106,50) | 2 | 1 |
| Baseline, Definite (n=106,50) | 104 | 49 |
| Month 2, Absent (n=106,50) | 37 | 4 |
| Month 2, Definite (n=106,50) | 69 | 46 |
| Month 6, Absent (n=108,45) | 64 | 29 |
| Month 6, Definite (n=108,45) | 44 | 16 |
| Month 12, Absent (n=103,47) | 81 | 37 |
| Month 12, Definite (n=103,47) | 22 | 10 |
BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. BCVA was assessed at each month from Month 1 through Month 6 or at each month from Month 1 through month 12, and the data were averaged. The outcome measure is reporting the change between baseline and average BCVA from Month 1 through Month 6 or from Month 1 through Month 12 (average BCVA - baseline BCVA). A positive change from baseline indicated improvement.
| letters | Ranibizumab | Sham Control |
|---|---|---|
| Average change from BL, month 1 through month 6 | 9.53 ± 10.467 | 4.68 ± 8.786 |
| Average change from BL, month 1 through month 12 | 9.99 ± 11.528 | 6.59 ± 10.666 |
VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using ETDRS-like visual acuity testing charts at a testing distance of 4 meters.
| Participants | Ranibizumab | Sham Control |
|---|---|---|
| Month 2,>=15 letters or reaching 84 let.(n=118,57) | 37 | 7 |
| Month 2, >=10 letters (n=118,57) | 50 | 8 |
| Month 2, >=5 letters (n=118,57) | 83 | 16 |
| Month 2, >=1 letter (118,57) | 101 | 27 |
| Month 6,>=15 letters or reaching 84 let.(n=118,54) | 53 | 20 |
| Month 6, >=10 letters (n=118,54) | 67 | 24 |
| Month 6, >= 5 letters (n=118,54) | 88 | 34 |
| Month 6, >= 1 letter (n=118,54) | 104 | 39 |
| Month 12,>=15 letters or reaching 84 let.;n=113,55 | 55 | 23 |
| Month 12, >=10 letters (n=113,55) | 64 | 28 |
| Month 12, >=5 letters (n=113,55) | 81 | 34 |
| Month 12, >=1 letter (n=113,55) | 100 | 42 |
VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using ETDRS-like visual acuity testing charts at a testing distance of 4 meters.
| Participants | Ranibizumab | Sham Control |
|---|---|---|
| Month 2, loss of >1 letter (n=118,57) | 10 | 24 |
| Month 2, loss of >5 letters (n=118,57) | 3 | 12 |
| Month 2, loss of >10 letters (n=118,57) | 1 | 5 |
| Month 2, loss of >15 letters (n=118,57) | 1 | 3 |
| Month 6, loss of >1 letter (n=118,54) | 10 | 9 |
| Month 6, loss of >5 letters (n=118,54) | 7 | 5 |
| Month 6, loss of >10 letters (n=118,54) | 6 | 2 |
| Month 6, loss of >15 letters (n=118,54) | 3 | 2 |
| Month 12, loss of >1 letter (n=113,55) | 9 | 10 |
| Month 12, loss of >5 letters (n=113,55) | 6 | 6 |
| Month 12, loss of >10 letters (n=113,55) | 5 | 4 |
| Month 12,loss of >15 letters (n=113,55) | 3 | 2 |
Rescue treatment with laser photocoagulation or periocular treatment could be administered at Month 1 only if the participant had a visual acuity loss of \> 5 letters due to disease activity from baseline to Month 1.
| Participants | Ranibizumab | Sham Control |
|---|---|---|
| Number of Participants With Requirement for Rescue Treatment at Month 1 | 0 | 1 |
The number of participants administered study treatments, according to treatment frequency, was assessed.
| Participants | Ranibizumab | Sham Control | Sham Without Ranibizumab |
|---|---|---|---|
| Frequency of injections = 0 | 0 | 0 | 7 |
| Frequency of injections = 1 | 12 | 5 | 0 |
| Frequency of injections = 2 | 12 | 6 | 0 |
| Frequency of injections = 3 | 19 | 7 | 0 |
| Frequency of injections = 4 | 13 | 6 | 0 |
| Frequency of injections = 5 | 9 | 5 | 0 |
| Frequency of injections = 6 | 11 | 6 | 0 |
| Frequency of injections = 7 | 2 | 2 | 0 |
| Frequency of injections = 8 | 8 | 1 | 0 |
| Frequency of injections = 9 | 5 | 4 | 0 |
| Frequency of injections = 10 | 7 | 10 | 0 |
| Frequency of injections = 11 | 6 | 0 | 0 |
| Frequency of injections = 12 | 15 | 0 | 0 |
The number of participants, administered re-treatments according to treatment frequency, was assessed. Re-treatment was defined as an administration of study medication following at least one non-missed visit where treatment was not administered in the study eye. Up to month 12, the maximum number of retreatments was 5.
| Paticipants | Ranibizumab | Sham Control | Sham Without Ranibizumab |
|---|---|---|---|
| Frequency of re-treatment = 1 | 25 | 21 | 0 |
| Frequency of re-treatment = 2 | 22 | 10 | 0 |
| Frequency of re-treatment = 3 | 9 | 4 | 0 |
| Frequency of re-treatment = 4 | 5 | 2 | 0 |
The total number of primary reasons for decisions to treat was assessed. A single participant could have had multiple primary reasons for treatment.
| Number of primary reasons | Ranibizumab | Sham Control | Sham Without Ranibizumab |
|---|---|---|---|
| Vision impairment | 29 | 9 | 0 |
| OCT abnormality | 522 | 306 | 1 |
| FA abnormality | 21 | 13 | 0 |
| Color fundus photography abnormality | 1 | 0 | 0 |
| Clinical abnormality | 6 | 0 | 0 |
| Without documentation | 1 | 0 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranibizumab | — | 9/119 (7.6%) | 42/119 (35.3%) |
| Sham With Ranibizumab | — | 4/52 (7.7%) | 19/52 (36.5%) |
| Sham Without Ranibizumab | — | 0/7 (0%) | 4/7 (57.1%) |
| Event | Ranibizumab | Sham With Ranibizumab | Sham Without Ranibizumab |
|---|---|---|---|
| FaecalomaGastrointestinal disorders | 0/119 | 1/52 | 0/7 |
| PyrexiaGeneral disorders | 0/119 | 1/52 | 0/7 |
| UrosepsisInfections and infestations | 0/119 | 1/52 | 0/7 |
| Rheumatic disorderMusculoskeletal and connective tissue disorders | 0/119 | 1/52 | 0/7 |
| Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/119 | 1/52 | 0/7 |
| OliguriaRenal and urinary disorders | 0/119 | 1/52 | 0/7 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/119 | 1/52 | 0/7 |
| Atrial fibrillationCardiac disorders | 1/119 | 0/52 | 0/7 |
| Retinal detachment (Fellow untreated eye)Eye disorders | 1/119 | 0/52 | 0/7 |
| Abdominal pain upperGastrointestinal disorders | 1/119 | 0/52 | 0/7 |
| Event | Ranibizumab | Sham With Ranibizumab | Sham Without Ranibizumab |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 14/119 | 9/52 | 1/7 |
| Choroidal neovascularisation (Study eye)Eye disorders | 3/119 | 0/52 | 1/7 |
| Eye inflammation (Study eye)Eye disorders | 0/119 | 0/52 | 1/7 |
| Foreign body sensation in eyes (Study eye)Eye disorders | 1/119 | 1/52 | 1/7 |
| Macular oedema (Study eye)Eye disorders | 0/119 | 0/52 | 1/7 |
| Ocular hyperaemia (Study eye)Eye disorders | 1/119 | 1/52 | 1/7 |
| Photopsia (Study eye)Eye disorders | 1/119 | 0/52 | 1/7 |
| Visual acuity reduced (Study eye)Eye disorders | 3/119 | 1/52 | 1/7 |
| PneumoniaInfections and infestations | 1/119 | 0/52 | 1/7 |
| Back painMusculoskeletal and connective tissue disorders | 6/119 | 0/52 | 1/7 |
| Age, Continuous(Years) | Ranibizumab | Sham Control | Total |
|---|---|---|---|
| Mean | 54.6 ± 15.07 | 51.9 ± 17.29 | 53.7 ± 15.85 |
| Sex: Female, Male(Participants) | Ranibizumab | Sham Control | Total |
|---|---|---|---|
| Female | 60 | 30 | 90 |
| Male | 59 | 29 | 88 |
The record gives a start of Sep 2013, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2016, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab
Choroidal Neovascularization →